DE10308355A1 - Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel - Google Patents

Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel Download PDF

Info

Publication number
DE10308355A1
DE10308355A1 DE10308355A DE10308355A DE10308355A1 DE 10308355 A1 DE10308355 A1 DE 10308355A1 DE 10308355 A DE10308355 A DE 10308355A DE 10308355 A DE10308355 A DE 10308355A DE 10308355 A1 DE10308355 A1 DE 10308355A1
Authority
DE
Germany
Prior art keywords
methyl
alkyl
tert
ylmethoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10308355A
Other languages
German (de)
English (en)
Inventor
Christian Dr. Stapper
Heiner Dr. Glombik
Eugen Dr. Falk
Jochen Dr. Goerlitzer
Dirk Dr. Gretzke
Stefanie Dr. Keil
Hans-Ludwig Dr. Schaefer
Wolfgang Dr. Wendler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to DE10308355A priority Critical patent/DE10308355A1/de
Priority to JP2006501885A priority patent/JP2006519193A/ja
Priority to EP04712490A priority patent/EP1599452B1/de
Priority to KR1020057016023A priority patent/KR20050106462A/ko
Priority to PL378437A priority patent/PL378437A1/pl
Priority to KR1020057015995A priority patent/KR20050106461A/ko
Priority to ES04712494T priority patent/ES2326418T3/es
Priority to AT04712503T priority patent/ATE435217T1/de
Priority to MXPA05008951A priority patent/MXPA05008951A/es
Priority to AT04712490T priority patent/ATE365159T1/de
Priority to EP04712494A priority patent/EP1599453B1/de
Priority to BRPI0407907-8A priority patent/BRPI0407907A/pt
Priority to CNB2004800054379A priority patent/CN100439345C/zh
Priority to PT04712503T priority patent/PT1599455E/pt
Priority to RU2005130002/04A priority patent/RU2005130002A/ru
Priority to AU2004215672A priority patent/AU2004215672B2/en
Priority to PL378130A priority patent/PL378130A1/pl
Priority to ES04712490T priority patent/ES2287700T3/es
Priority to PCT/EP2004/001579 priority patent/WO2004076427A1/de
Priority to JP2006501886A priority patent/JP2006519194A/ja
Priority to RU2005129992/04A priority patent/RU2005129992A/ru
Priority to DE502004004139T priority patent/DE502004004139D1/de
Priority to CNB2004800054769A priority patent/CN100439347C/zh
Priority to PT04712494T priority patent/PT1599453E/pt
Priority to PCT/EP2004/001578 priority patent/WO2004076426A1/de
Priority to CNB2004800054985A priority patent/CN100398526C/zh
Priority to BRPI0407814-4A priority patent/BRPI0407814A/pt
Priority to AU2004215673A priority patent/AU2004215673B2/en
Priority to DK04712490T priority patent/DK1599452T3/da
Priority to MXPA05008988A priority patent/MXPA05008988A/es
Priority to KR1020057015851A priority patent/KR20050105492A/ko
Priority to BRPI0407758-0A priority patent/BRPI0407758A/pt
Priority to EP04712503A priority patent/EP1599455B1/de
Priority to RU2005129995/04A priority patent/RU2005129995A/ru
Priority to CA002516620A priority patent/CA2516620A1/en
Priority to DK04712503T priority patent/DK1599455T3/da
Priority to OA1200500247A priority patent/OA13034A/en
Priority to AT04712494T priority patent/ATE430738T1/de
Priority to PCT/EP2004/001586 priority patent/WO2004076428A1/de
Priority to DK04712494T priority patent/DK1599453T3/da
Priority to JP2006501892A priority patent/JP2006519199A/ja
Priority to DE502004009690T priority patent/DE502004009690D1/de
Priority to PT04712490T priority patent/PT1599452E/pt
Priority to DE502004009453T priority patent/DE502004009453D1/de
Priority to OA1200500248A priority patent/OA13035A/en
Priority to CA002517381A priority patent/CA2517381A1/en
Priority to MXPA05008995A priority patent/MXPA05008995A/es
Priority to PL377735A priority patent/PL377735A1/pl
Priority to ES04712503T priority patent/ES2329366T3/es
Priority to AU2004215677A priority patent/AU2004215677B2/en
Priority to CA002517386A priority patent/CA2517386A1/en
Priority to YUP-2005/0594A priority patent/RS20050594A/sr
Priority to TW093104704A priority patent/TW200500349A/zh
Priority to TW093104697A priority patent/TW200508210A/zh
Priority to TW093104705A priority patent/TW200510352A/zh
Priority to US10/788,997 priority patent/US7365084B2/en
Priority to ARP040100635A priority patent/AR043432A1/es
Priority to US10/788,996 priority patent/US7259177B2/en
Priority to PE2004000203A priority patent/PE20050292A1/es
Priority to ARP040100636A priority patent/AR043433A1/es
Priority to UY28209A priority patent/UY28209A1/es
Priority to CL200400392A priority patent/CL2004000392A1/es
Priority to ARP040100629A priority patent/AR043427A1/es
Priority to UY28210A priority patent/UY28210A1/es
Priority to PE2004000206A priority patent/PE20040959A1/es
Priority to PA20048596801A priority patent/PA8596801A1/es
Priority to CL200400391A priority patent/CL2004000391A1/es
Priority to PE2004000205A priority patent/PE20050293A1/es
Priority to US10/789,017 priority patent/US7335671B2/en
Priority to SA04250153A priority patent/SA04250153A/ar
Publication of DE10308355A1 publication Critical patent/DE10308355A1/de
Priority to ZA200505765A priority patent/ZA200505765B/en
Priority to ZA200505768A priority patent/ZA200505768B/en
Priority to IL170314A priority patent/IL170314A/en
Priority to IL170316A priority patent/IL170316A/en
Priority to HR20050743A priority patent/HRP20050743A2/xx
Priority to MA28460A priority patent/MA27737A1/fr
Priority to CO05085499A priority patent/CO5690578A2/es
Priority to HR20050744A priority patent/HRP20050744A2/xx
Priority to TNP2005000206A priority patent/TNSN05206A1/en
Priority to MA28465A priority patent/MA27742A1/fr
Priority to TNP2005000204A priority patent/TNSN05204A1/en
Priority to EC2005005985A priority patent/ECSP055985A/es
Priority to HR20050742A priority patent/HRP20050742A2/xx
Priority to EC2005005986A priority patent/ECSP055986A/es
Priority to MA28459A priority patent/MA27736A1/fr
Priority to CO05085508A priority patent/CO5690580A2/es
Priority to NO20054408A priority patent/NO20054408L/no
Priority to NO20054398A priority patent/NO20054398L/no
Priority to NO20054396A priority patent/NO20054396L/no
Priority to US11/839,950 priority patent/US20080015238A1/en
Priority to US12/013,806 priority patent/US7872034B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
DE10308355A 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel Withdrawn DE10308355A1 (de)

Priority Applications (91)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
JP2006501885A JP2006519193A (ja) 2003-02-27 2004-02-19 ２型糖尿病およびアテローム性動脈硬化症の治療のためのｐｐａｒモジュレーターとしての３−メチル−２−（３−（２−フェニル−オキサゾール−４−イルメトキシ）−シクロヘキサンカルボニル−アミノ酪酸誘導体および関連化合物
EP04712490A EP1599452B1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
KR1020057016023A KR20050106462A (ko) 2003-02-27 2004-02-19 2형 당뇨병 및 죽상동맥경화증 치료용 ｐｐａｒ조절제로서의3-메틸-2-(3-(2-페닐-옥사졸-4-일메톡시)-사이클로헥산카보닐-아미노 부티르산 유도체 및 관련 화합물
PL378437A PL378437A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
KR1020057015995A KR20050106461A (ko) 2003-02-27 2004-02-19 타입 2 당뇨병과 죽상동맥경화증 치료에 ｐｐａｒ 조절제로사용되는 3-(2-페닐-옥사졸-4-일 메톡시)사이클로헥실메톡시 아세트산 유도체 및 이와 관련된화합물
ES04712494T ES2326418T3 (es) 2003-02-27 2004-02-19 Derivados de acido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonilamino)-butirico y compuestos relacionados en calidad de moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis.
AT04712503T ATE435217T1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)- cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
MXPA05008951A MXPA05008951A (es) 2003-02-27 2004-02-19 Derivados de acido 3-metil -2-(3- (2-fenil -oxazol-4 -ilmetoxi) -ciclohexanocarbonil -aminobutirico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis.
AT04712490T ATE365159T1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
EP04712494A EP1599453B1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
BRPI0407907-8A BRPI0407907A (pt) 2003-02-27 2004-02-19 derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
CNB2004800054379A CN100439345C (zh) 2003-02-27 2004-02-19 作为用于治疗 2型糠尿病和动脉硬化症的ppar调节剂的 3 - ( 2 -苯基 -噁唑-4-基甲氧基)环己基甲氧基乙酸衍生物和相关化合物
PT04712503T PT1599455E (pt) 2003-02-27 2004-02-19 Derivados do ácido 4-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexiloxi)- butanóico e compostos relacionados como moduladores de ppar para o tratamento de diabetes de tipo 2 e aterosclerose
RU2005130002/04A RU2005130002A (ru) 2003-02-27 2004-02-19 Производные 3-метил-2-(2-фенилоксазол-4-илметокси)циклогексанкарбониламино)масляной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза
AU2004215672A AU2004215672B2 (en) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis
PL378130A PL378130A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
ES04712490T ES2287700T3 (es) 2003-02-27 2004-02-19 Derivados de acido 3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexil-metoxy-acetico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis.
PCT/EP2004/001579 WO2004076427A1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
JP2006501886A JP2006519194A (ja) 2003-02-27 2004-02-19 ２型糖尿病およびアテローム性動脈硬化症の治療のためのｐｐａｒモジュレーターとしての３−（２−フェニル−オキサゾール−４−イルメトキシ）シクロヘキシルメトキシ酢酸誘導体および関連化合物
RU2005129992/04A RU2005129992A (ru) 2003-02-27 2004-02-19 Производные 4-(2-фенилоксазол-4-илметокси) циклогексилокси) бутановой кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза
DE502004004139T DE502004004139D1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
CNB2004800054769A CN100439347C (zh) 2003-02-27 2004-02-19 作为ppar调节剂用于治疗2型糖尿病和动脉粥样硬化的4-(3-(2-苯基噁唑-4-基甲氧基)-环己氧基)-丁酸衍生物及相关化合物
PT04712494T PT1599453E (pt) 2003-02-27 2004-02-19 Derivados do ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)- ciclo-hexanocarbonil-amino)-butírico e compostos relacionados como moduladores de ppar para o tratamento de diabetes de tipo 2 e aterosclerose
PCT/EP2004/001578 WO2004076426A1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
CNB2004800054985A CN100398526C (zh) 2003-02-27 2004-02-19 作为用于治疗2型糖尿病和动脉粥样硬化的ppar调节剂的3－甲基－2－(3－(2－苯基－唑－4－基甲氧基)环己烷羰基－氨基)丁酸衍生物和相关化合物
BRPI0407814-4A BRPI0407814A (pt) 2003-02-27 2004-02-19 derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose
AU2004215673A AU2004215673B2 (en) 2003-02-27 2004-02-19 3-(2-Phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as PPAR modulators for treating type 2 diabetes and arteriosclerosis
DK04712490T DK1599452T3 (da) 2003-02-27 2004-02-19 3- (2-phenyloxazol- 4-ylmethoxy) - cyclohexylmethoxyeddikesyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerosw
MXPA05008988A MXPA05008988A (es) 2003-02-27 2004-02-19 Derivados de acido 3-(2-fenil-oxazol-4-ilmetoxi) ciclohexilmetoxiacetico y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis.
KR1020057015851A KR20050105492A (ko) 2003-02-27 2004-02-19 2형 당뇨병 및 아테롬성경화증 치료용 ｐｐａｒ조절제로서의4-(3-(2-페닐옥사졸-4-일메톡시)-사이클로헥실옥시)-부탄산유도체 및 관련 화합물
BRPI0407758-0A BRPI0407758A (pt) 2003-02-27 2004-02-19 derivados de 3-(2-fenil-oxazol-4-ilmetóxi)-ciclohexilmetóxi-acético e compostos afins como modula-dores de ppar para o tratamento de diabetes do tipo 2 e aterosclerose.
EP04712503A EP1599455B1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
RU2005129995/04A RU2005129995A (ru) 2003-02-27 2004-02-19 Производные 3-(2-фенилоксазол-4-илметокси) циклогексилметоксиуксусной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза
CA002516620A CA2516620A1 (en) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
DK04712503T DK1599455T3 (da) 2003-02-27 2004-02-19 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose
OA1200500247A OA13034A (en) 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino)-butyric acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis.
AT04712494T ATE430738T1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)- cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DK04712494T DK1599453T3 (da) 2003-02-27 2004-02-19 3-Methyl-2-(3-(2-phenyloxazol-4-ylmethyoxy)cyclohexancarbonylamino)smörsyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerose
JP2006501892A JP2006519199A (ja) 2003-02-27 2004-02-19 ２型糖尿病およびアテローム性動脈硬化症の治療のためのｐｐａｒモジュレーターとしての４−（３−（２−フェニル−オキサゾール−４−イルメトキシ）−シクロヘキシルオキシ）−ブタン酸誘導体および関連化合物
DE502004009690T DE502004009690D1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
PT04712490T PT1599452E (pt) 2003-02-27 2004-02-19 Derivados do ácido 3 - ( 2-fenil-oxazol-4-ilmetoxi ) -ciclo-hexilmetoxi-acético e composto relacionados como moduladores ppar para tratamento de diabetes do tipo2 e aterosclerose.
DE502004009453T DE502004009453D1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
OA1200500248A OA13035A (en) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexylmethoxy acetic acid derivatives and related compounds usedas PPAR modulators for treating type 2 diabetes a nd atherosclerosis.
CA002517381A CA2517381A1 (en) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
MXPA05008995A MXPA05008995A (es) 2003-02-27 2004-02-19 Derivados de acido 4 - (3-(2-feniloxazol - 4 - ilmetoxi) ciclohexiloxi) - butanoico y compuestos relacionados como moduladores de ppar para tratar la diabetes tipo 2 y la aterosclerosis.
PL377735A PL377735A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
ES04712503T ES2329366T3 (es) 2003-02-27 2004-02-19 Derivados de acido 4-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexiloxi)-butanoico y compuestos relacionados en calidad de moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis.
AU2004215677A AU2004215677B2 (en) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as PPAR modulators for treating diabetes of type 2 and atherosclerosis
CA002517386A CA2517386A1 (en) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
YUP-2005/0594A RS20050594A (en) 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
TW093104704A TW200500349A (en) 2003-02-27 2004-02-25 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
TW093104697A TW200508210A (en) 2003-02-27 2004-02-25 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
TW093104705A TW200510352A (en) 2003-02-27 2004-02-25 Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
US10/788,997 US7365084B2 (en) 2003-02-27 2004-02-27 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals
ARP040100635A AR043432A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
US10/788,996 US7259177B2 (en) 2003-02-27 2004-02-27 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
PE2004000203A PE20050292A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos
ARP040100636A AR043433A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos
UY28209A UY28209A1 (es) 2003-02-27 2004-02-27 Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos.
CL200400392A CL2004000392A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra
ARP040100629A AR043427A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion, y su empleo como medicamentos
UY28210A UY28210A1 (es) 2003-02-27 2004-02-27 Derivados de ácido acético sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos.
PE2004000206A PE20040959A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion
PA20048596801A PA8596801A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos
CL200400391A CL2004000391A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.
PE2004000205A PE20050293A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
US10/789,017 US7335671B2 (en) 2003-02-27 2004-02-27 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
SA04250153A SA04250153A (ar) 2003-02-27 2004-06-09 عمليات لتحضير مشتقات أحماض أمينية بها استبدال بسيكلو ألكيل ميثوكسي ، واستخدامها كمستحضرات دوائية
ZA200505765A ZA200505765B (en) 2003-02-27 2005-07-19 4(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
ZA200505768A ZA200505768B (en) 2003-02-27 2005-07-19 3-(2-Phenyl-oxazol-4-ylmethoxy) cyclohexylmethoxy acetic acid derivatives and related compounds usedas ppar modulators for treating type 2 diabetes a nd arteriosclerosis.
IL170314A IL170314A (en) 2003-02-27 2005-08-16 4 - (3 -(2 - phenyl - oxazol - 4 - ylmethoxy) - cyclohexyloxy) - butane acid derivatives and related compounds, pharmaceutical compositions comprising them and use thereof
IL170316A IL170316A (en) 2003-02-27 2005-08-16 Cycloalkyl-methoxy substituted acetic acid derivatives and pharmaceutical compositions comprising them
HR20050743A HRP20050743A2 (en) 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
MA28460A MA27737A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
CO05085499A CO5690578A2 (es) 2003-02-27 2005-08-26 Derivados de acido 4-(3-(2-feniloxazol-4-ilmetoxi)ciclohexiloxi)-butanoico y compuestos relacionados como moduladores de ppar para tratar la diabetes tipo 2 y la aterosclerosis
HR20050744A HRP20050744A2 (en) 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
TNP2005000206A TNSN05206A1 (en) 2003-02-27 2005-08-26 3-methyl-2-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
MA28465A MA27742A1 (fr) 2003-02-27 2005-08-26 Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose.
TNP2005000204A TNSN05204A1 (en) 2003-02-27 2005-08-26 3-2-phenyl-oxazol-4-ylmethoxy)cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
EC2005005985A ECSP055985A (es) 2003-02-27 2005-08-26 Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis
HR20050742A HRP20050742A2 (en) 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
EC2005005986A ECSP055986A (es) 2003-02-27 2005-08-26 Derivados de ácido 3-(2-fenil-oxazol-4-ilmetoxi)ciclohexilmetoxiacético y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis
MA28459A MA27736A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
CO05085508A CO5690580A2 (es) 2003-02-27 2005-08-26 Derivados de acido 3-(2-fenil-oxazol-4-ilmetoxi)ciclohexilmetoxiacetico y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis
NO20054408A NO20054408L (no) 2003-02-27 2005-09-22 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NO20054398A NO20054398L (no) 2003-02-27 2005-09-22 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20054396A NO20054396L (no) 2003-02-27 2005-09-22 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
US11/839,950 US20080015238A1 (en) 2003-02-27 2007-08-16 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
US12/013,806 US7872034B2 (en) 2003-02-27 2008-01-14 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
DE10308355A1 true DE10308355A1 (de) 2004-12-23

Family

ID=32920629

Family Applications (4)

Application Number Title Priority Date Filing Date
DE10308355A Withdrawn DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE502004004139T Expired - Lifetime DE502004004139D1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE502004009453T Expired - Lifetime DE502004009453D1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE502004009690T Expired - Lifetime DE502004009690D1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE502004004139T Expired - Lifetime DE502004004139D1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE502004009453T Expired - Lifetime DE502004009453D1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE502004009690T Expired - Lifetime DE502004009690D1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Country Status (34)

Country Link
US (5) US7259177B2 (US07259177-20070821-C00218.png)
EP (3) EP1599452B1 (US07259177-20070821-C00218.png)
JP (3) JP2006519193A (US07259177-20070821-C00218.png)
KR (3) KR20050106461A (US07259177-20070821-C00218.png)
CN (3) CN100398526C (US07259177-20070821-C00218.png)
AR (3) AR043427A1 (US07259177-20070821-C00218.png)
AT (3) ATE365159T1 (US07259177-20070821-C00218.png)
AU (3) AU2004215673B2 (US07259177-20070821-C00218.png)
BR (3) BRPI0407758A (US07259177-20070821-C00218.png)
CA (3) CA2517381A1 (US07259177-20070821-C00218.png)
CL (2) CL2004000392A1 (US07259177-20070821-C00218.png)
CO (2) CO5690580A2 (US07259177-20070821-C00218.png)
DE (4) DE10308355A1 (US07259177-20070821-C00218.png)
DK (3) DK1599455T3 (US07259177-20070821-C00218.png)
EC (2) ECSP055985A (US07259177-20070821-C00218.png)
ES (3) ES2326418T3 (US07259177-20070821-C00218.png)
HR (3) HRP20050743A2 (US07259177-20070821-C00218.png)
IL (2) IL170316A (US07259177-20070821-C00218.png)
MA (3) MA27736A1 (US07259177-20070821-C00218.png)
MX (3) MXPA05008951A (US07259177-20070821-C00218.png)
NO (3) NO20054408L (US07259177-20070821-C00218.png)
OA (2) OA13035A (US07259177-20070821-C00218.png)
PA (1) PA8596801A1 (US07259177-20070821-C00218.png)
PE (3) PE20040959A1 (US07259177-20070821-C00218.png)
PL (3) PL378437A1 (US07259177-20070821-C00218.png)
PT (3) PT1599455E (US07259177-20070821-C00218.png)
RS (1) RS20050594A (US07259177-20070821-C00218.png)
RU (3) RU2005129992A (US07259177-20070821-C00218.png)
SA (1) SA04250153A (US07259177-20070821-C00218.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00218.png)
TW (3) TW200508210A (US07259177-20070821-C00218.png)
UY (2) UY28210A1 (US07259177-20070821-C00218.png)
WO (3) WO2004076428A1 (US07259177-20070821-C00218.png)
ZA (2) ZA200505765B (US07259177-20070821-C00218.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
BRPI0617207A2 (pt) 2005-09-29 2011-07-19 Sanofi Aventis derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
US8128969B2 (en) 2006-08-10 2012-03-06 Mimozax Co., Ltd. Hypoglycemic composition containing acacia bark derivative
CN101801906A (zh) 2007-08-16 2010-08-11 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
CN103435593B (zh) 2008-02-29 2015-01-28 日产化学工业株式会社 噻吩化合物及其中间体的制造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116224736A (zh) 2017-12-13 2023-06-06 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
IL142649A (en) 1996-12-31 2004-12-15 Reddy Research Foundation Azole derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
CN1183113C (zh) * 1999-04-28 2005-01-05 阿文蒂斯药物德国有限公司 作为ppar受体配体的三芳基酸衍生物
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ， インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
US6967201B1 (en) 1999-07-29 2005-11-22 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
PL353367A1 (en) 1999-09-01 2003-11-17 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
PL357118A1 (en) 1999-12-03 2004-07-12 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
DK1283735T4 (da) 2000-03-31 2013-02-04 Royalty Pharma Collection Trust Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
EP1277745A4 (en) 2000-04-25 2004-09-15 Kyorin Seiyaku Kk NEW STABLE CRYSTALS OF THIAZOLIDINDION DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
DE60129806T2 (de) 2000-04-28 2007-12-06 Asahi Kasei Pharma Corp. Neue bizyklische verbindungen
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
PT1294682E (pt) 2000-06-09 2004-09-30 Aventis Pharma Gmbh Derivados de acilfenilureia processo para a sua preparacao e sua aplicacao como medicamentos
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
NZ523804A (en) * 2000-08-23 2004-09-24 Lilly Co Eli Peroxisome proliferator activated receptor agonists
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1345895B1 (de) 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
ATE370130T1 (de) * 2000-12-25 2007-09-15 Ono Pharmaceutical Co Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
MXPA03007284A (es) 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
PL367077A1 (en) * 2001-06-07 2005-02-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
RU2330846C2 (ru) 2001-08-31 2008-08-10 Санофи-Авентис Дойчланд Гмбх Диарилциклоалкильные производные, способ их получения и их применение в качестве ppar-активаторов
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
PT1599453E (pt) 2009-07-14
CO5690578A2 (es) 2006-10-31
ES2287700T3 (es) 2007-12-16
AR043432A1 (es) 2005-07-27
ATE365159T1 (de) 2007-07-15
JP2006519194A (ja) 2006-08-24
AU2004215677B2 (en) 2010-01-07
OA13035A (en) 2006-11-10
ES2326418T3 (es) 2009-10-09
CL2004000391A1 (es) 2005-01-07
PL378437A1 (pl) 2006-04-03
TW200500349A (en) 2005-01-01
RS20050594A (en) 2007-12-31
BRPI0407758A (pt) 2006-02-14
PT1599455E (pt) 2009-09-29
HRP20050742A2 (en) 2006-09-30
MXPA05008951A (es) 2005-11-04
UY28209A1 (es) 2004-09-30
BRPI0407907A (pt) 2006-02-14
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
EP1599453A1 (de) 2005-11-30
AR043433A1 (es) 2005-07-27
ZA200505765B (en) 2006-05-31
CL2004000392A1 (es) 2005-04-22
MXPA05008988A (es) 2005-10-18
EP1599455A1 (de) 2005-11-30
JP2006519199A (ja) 2006-08-24
US7335671B2 (en) 2008-02-26
RU2005130002A (ru) 2006-01-27
EP1599453B1 (de) 2009-05-06
MXPA05008995A (es) 2005-10-18
EP1599452A1 (de) 2005-11-30
US20040209920A1 (en) 2004-10-21
DK1599453T3 (da) 2009-08-24
ECSP055986A (es) 2006-01-16
CA2517386A1 (en) 2004-09-10
RU2005129992A (ru) 2006-02-10
DK1599452T3 (da) 2007-10-01
JP2006519193A (ja) 2006-08-24
OA13034A (en) 2006-11-10
CA2516620A1 (en) 2004-09-10
PL377735A1 (pl) 2006-02-20
US20050101637A1 (en) 2005-05-12
ATE435217T1 (de) 2009-07-15
NO20054396L (no) 2005-11-11
PT1599452E (pt) 2007-09-12
MA27736A1 (fr) 2006-02-01
EP1599452B1 (de) 2007-06-20
DE502004004139D1 (de) 2007-08-02
CN1753881A (zh) 2006-03-29
HRP20050744A2 (en) 2006-09-30
US7365084B2 (en) 2008-04-29
CN100439347C (zh) 2008-12-03
KR20050106461A (ko) 2005-11-09
SA04250153A (ar) 2005-12-03
US7259177B2 (en) 2007-08-21
DE502004009453D1 (de) 2009-06-18
PE20050292A1 (es) 2005-05-24
PE20050293A1 (es) 2005-05-24
US20080167354A1 (en) 2008-07-10
BRPI0407814A (pt) 2006-02-14
ZA200505768B (en) 2005-11-23
KR20050105492A (ko) 2005-11-04
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
CN1756748A (zh) 2006-04-05
DE502004009690D1 (de) 2009-08-13
CN100439345C (zh) 2008-12-03
WO2004076428A1 (de) 2004-09-10
WO2004076426A1 (de) 2004-09-10
TNSN05206A1 (en) 2007-06-11
WO2004076427A1 (de) 2004-09-10
AU2004215672A1 (en) 2004-09-10
CA2517381A1 (en) 2004-09-10
ECSP055985A (es) 2006-01-16
TNSN05204A1 (en) 2007-06-11
AU2004215672B2 (en) 2010-01-07
IL170314A (en) 2010-11-30
MA27737A1 (fr) 2006-02-01
PE20040959A1 (es) 2005-01-17
ATE430738T1 (de) 2009-05-15
AR043427A1 (es) 2005-07-27
EP1599455B1 (de) 2009-07-01
US20050215596A1 (en) 2005-09-29
UY28210A1 (es) 2004-09-30
MA27742A1 (fr) 2006-02-01
PL378130A1 (pl) 2006-03-06
NO20054398L (no) 2005-11-02
CN100398526C (zh) 2008-07-02
US7872034B2 (en) 2011-01-18
KR20050106462A (ko) 2005-11-09
CO5690580A2 (es) 2006-10-31
AU2004215673B2 (en) 2009-10-01
AU2004215677A1 (en) 2004-09-10
NO20054396D0 (no) 2005-09-22
TW200510352A (en) 2005-03-16
RU2005129995A (ru) 2006-01-27
NO20054408D0 (no) 2005-09-22
ES2329366T3 (es) 2009-11-25
TW200508210A (en) 2005-03-01
NO20054398D0 (no) 2005-09-22
DK1599455T3 (da) 2009-11-09
CN1753879A (zh) 2006-03-29
AU2004215673A1 (en) 2004-09-10
US20080015238A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
EP1425014B1 (de) Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
DE10308355A1 (de) Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US20040122069A1 (en) Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
EP1789403A1 (de) N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl-bernsteinsäureamid derivate und verwandte verbindungen als ppar-liganden (peroxisomen-proliferatoren-aktivierte rezeptoren) zur behandlung von hyperlipidämie und diabetes
DE10308353A1 (de) Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10223273A1 (de) Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308356A1 (de) Cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102005029382B3 (de) Alkoxymethylyl-substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308354A1 (de) Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Legal Events

Date Code Title Description
OR8 Request for search as to paragraph 43 lit. 1 sentence 1 patent law
8105 Search report available
8127 New person/name/address of the applicant

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,

8130 Withdrawal